Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 amlitelimab in moderate-to-severe atopic dermatitis after inadequate response to prior biologic or oral JAK inhibitor therapy
CTR20241770Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Started Sep 2024; status: active.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241770.